RxDoctor Payments Data

Hayley Craner

Psychiatric/Mental Health · Marcellus, NYNPI 1285203703

Payments from drug & device makers

$727in general payments, 2019–2025

Across 29 payments — averaging $25.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$180
  • Sunovion Pharmaceuticals Inc.$157
  • Otsuka America Pharmaceutical, Inc.$131
  • AbbVie$70
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$65
  • Axsome Therapeutics, Inc.$29
  • plus $95 from 5 others

What the payments were for

  • Food & beverage$727100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$727 in reported general payments places this provider in the 60th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$7,955
Medicare patients
15
Services billed
87

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl29$39,634
Aripiprazole71$2,165
Hydroxyzine Hcl49$1,771
Ziprasidone Hcl13$1,372
Perphenazine31$1,362
Buspirone Hcl120$1,327
Lamotrigine91$1,289
Venlafaxine Hcl ErVenlafaxine Hcl77$859
Escitalopram Oxalate47$845
Bupropion XlBupropion Hcl32$765
Risperidone49$716
Trazodone Hcl76$614
Quetiapine Fumarate55$413
Benztropine Mesylate36$400
Sertraline Hcl73$373

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$70$39,63429 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in Marcellus

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →